A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 8.02 MB, PDF document
Inherited bleeding disorders such as Glanzmann thrombasthenia (GT) lack prophylactic treatment options. As a result, serious bleeding episodes are treated acutely with blood product transfusions or frequent, repeated intravenous administration of recombinant activated coagulation factor VII (rFVIIa). Here we describe HMB-001, a bispecific antibody designed to bind and accumulate endogenous FVIIa and deliver it to sites of vascular injury by targeting it to the TREM (triggering receptor expressed on myeloid cells)-like transcript-1 (TLT-1) receptor that is selectively expressed on activated platelets. In healthy nonhuman primates, HMB-001 prolonged the half-life of endogenous FVIIa, resulting in its accumulation. Mouse bleeding studies confirmed antibody-mediated potentiation of FVIIa hemostatic activity by TLT-1 targeting. In ex vivo models of GT, HMB-001 localized FVIIa on activated platelets and potentiated fibrin-dependent platelet aggregation. Taken together, these results indicate that HMB-001 has the potential to offer subcutaneous prophylactic treatment to prevent bleeds in people with GT and other inherited bleeding disorders, with a low-frequency dosing regimen.
Original language | English |
---|---|
Journal | Nature Cardiovascular Research |
Volume | 3 |
Issue number | 2 |
Pages (from-to) | 166-185 |
Number of pages | 20 |
DOIs | |
Publication status | Published - 2024 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:
© The Author(s) 2024.
ID: 383397919